Northern Lincolnshire Formulary

	Northern Lincolnshire
	Formulary

Search

Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter

Notes:

NHS England - The Cancer Drugs Fund

Please refer to the North East Yorkshire and Humber Clinical Alliance for full cancer guidelines and chemotherapy regimens.

North East Yorkshire and Humber Clinical Alliance

Details...

08.03.04

Hormone antagonists

08.03.04.01

Breast cancer

Anastrozole
(Breast cancer)

Formulary

1mg Tablet

Exemestane

Formulary

Tablets 25mg

Fulvestrant (Faslodex^®)

Formulary

Injection

NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer

Goserelin (Zoladex^®)
(Breast cancer)

Formulary

Injection 3.6mg, 10.8mg

Letrozole

Formulary

Tablet

Tamoxifen
(Breast cancer/ mastocytosis)

Formulary

Tablets 10mg, 20mg.

Toremifene (Fareston^®)

Formulary

Tablets 60mg

NICE CG164: Familial Breast Cancer

NICE CG80: Early and locally advanced breast cancer

NICE CG81: Breast cancer (advanced)

NICE TA112: Breast cancer (early) - hormonal treatments

08.03.04.02

Prostate cancer and gonadorelin analogues

Radium-223 dichloride
(Xofigo^®)

Formulary

NICE TA376: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases

NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases

NICE CG175: Prostate cancer

08.03.04.02

Gonadorelin analogues

Degarelix (Firmagon^®)

Formulary

injection

NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer

08.03.04.02

Anti-androgens

Abiraterone (Zytiga^®)

Formulary

tablet

NICE TA259: Abiraterone for castration resistant prostate cancer

NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

Bicalutamide

Formulary

50mg and 150mg tablets

Buserelin
(Prostate)

Formulary

Cyproterone

Formulary

Tablet

Enzalutamide (Xtandi^®)

Formulary

capsule

NICE TA316: Enzalutamide for prostate cancer

NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

Flutamide

Formulary

Tablets

Goserelin (Zoladex^®)

Formulary

3.6mg Injection

Goserelin (Zoladex^® LA)

Formulary

10.8mg Injection

Leuprorelin Acetate (Prostap^® 3)

Formulary

11.25mg Injection

Leuprorelin Acetate (Prostap^® SR)

Formulary

3.75mg Injection

Triptorelin (Decapeptyl^®)
(Malignancy)

Formulary

Injection

08.03.04.03

Somatostatin analogues

Lanreotide

Formulary

Injection - Prefilled syringe

Octreotide (Sandostatin Lar^®)

Formulary

50 mcg/ml, 100 mcg/ml injection

Octreotide (Sandostatin^®)

Formulary

injection

....

Key

	Notes
	Section Title (top level)
	Section Title (sub level)
	First Choice item
	Non Formulary section
	Restricted Drug
	Unlicensed
	Display tracking information
	Link to adult BNF
	Link to children's BNF
	Link to SPCs
	Scottish Medicines Consortium

	Cytotoxic Drug
	Controlled Drug
	High Cost Medicine
	Cancer Drugs Fund
	NHS England
	Homecare
	CCG

Traffic Light Status Information

Status	Description
	Green -Medicines suitable for routine use within primary care and Secondary care Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
	Amber- Medicines suitable to be prescribed in primary care after specialist /Consultant recommendation or initiation. A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust Medicines and Therapeutic Committee and approved by the Area Prescribing Committee.
	Red-Hospital initiation and continuation only
	AMBER SHARE CARE PROTOCOL- Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised
	To be supplied from the appropriate commissioned provider.
	GREEN 2- to be prescribed by primary care only
	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)